Long Shortz with Rhythm: $3.75M placement to accelerate cancer and genetic diagnostics

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO and managing director David Atkins about the company’s recently completed $3.75 million placement.

Atkins explains that strong demand from both existing and new shareholders allowed Rhythm to close the raise at the maximum limit, providing fresh capital to support its growth strategy.

With multiple streams of newsflow expected over the next 12 months, Atkins says Rhythm is positioned for a pivotal period of growth and value creation.

This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.